{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:20:15Z","timestamp":1785280815401,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18lk1601003h0001"],"award-info":[{"award-number":["JP18lk1601003h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018036","name":"Nippon Shinyaku Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jjcc.2025.12.022","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:09:30Z","timestamp":1767773370000},"page":"29-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world treatment practices of selexipag and parenteral prostacyclin (PGI2) analogs for pulmonary arterial hypertension in Japan: Retrospective study of the Japan PH Registry"],"prefix":"10.1016","volume":"88","author":[{"given":"Yuichi","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kumamaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Inami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohtaro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shigeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jjcc.2025.12.022_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107576","article-title":"Pulmonary arterial hypertension specific therapy: the old and the new","volume":"214","author":"Zolty","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0010","series-title":"Public Health Administration report, 2024 (data from 2023)","author":"Japan Intractable Diseases Information Center","year":"2024"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0015","series-title":"Population census 2023","author":"Statistics Bureau of Japan","year":"2023"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0020","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0025","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1161\/CIRCULATIONAHA.114.006974","article-title":"Advances in therapeutic interventions for patients with pulmonary arterial hypertension","volume":"130","author":"Humbert","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0030","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1253\/circj.CJ-66-0158","article-title":"Guidelines for the treatment of pulmonary hypertension (JCS 2017\/JPCPHS 2017)","volume":"83","author":"Fukuda","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1183\/16000617.0083-2016","article-title":"Practical considerations for therapies targeting the prostacyclin pathway","volume":"25","author":"Farber","year":"2016","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0040","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacasi.2022.02.011","article-title":"Changes in the characteristics and initial treatments of pulmonary hypertension between 2008 and 2020 in Japan","volume":"2","author":"Tamura","year":"2022","journal-title":"JACC Asia"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0055","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0060","article-title":"Comparative efficacy and safety of prostacyclin analogs for pulmonary arterial hypertension: a network meta-analysis","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erc.12.160","article-title":"Treprostinil for the treatment of pulmonary arterial hypertension","volume":"11","author":"Torres","year":"2013","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0070","first-page":"32","article-title":"Real-world experience of selexipag titration in pulmonary arterial hypertension","volume":"28","author":"Cullivan","year":"2021","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0075","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40265-016-0549-4","article-title":"Selexipag: first global approval","volume":"76","author":"Scott","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0080","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0085","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.201507-1456OC","article-title":"Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension","volume":"192","author":"Rhee","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0090","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","article-title":"Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension","volume":"204","author":"Boucly","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0095","author":"United PH Registry in Japan"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0100","doi-asserted-by":"crossref","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12016","article-title":"Real-world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting","volume":"12","author":"Balasubramanian","year":"2022","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0110","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.chest.2018.03.050","article-title":"Mortality in patients with pulmonary arterial hypertension treated with continuous prostanoids","volume":"154","author":"Bartolome","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221132735","article-title":"Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina","volume":"16","author":"Lescano","year":"2022","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0120","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.healun.2023.09.016","article-title":"Disease characteristics, treatments, and outcomes of patients with pulmonary arterial hypertension treated with selexipag in real-world settings from the SPHERE registry (SelexiPag: tHe usErs dRug rEgistry)","volume":"43","author":"McLaughlin","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.991586","article-title":"Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients","volume":"9","author":"Cui","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0130","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1007\/s12325-024-02946-2","article-title":"Four-strata risk assessment in patients with pulmonary arterial hypertension treated with selexipag in real-world settings (EXPOSURE Study)","volume":"41","author":"Lange","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12403","article-title":"Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): real-world experience from EXPOSURE","volume":"14","author":"Gaine","year":"2024","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0140","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02493-2016","article-title":"Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension","volume":"50","author":"Gaine","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijcard.2018.08.082","article-title":"Targeted therapy of pulmonary arterial hypertension: updated recommendations from the Cologne Consensus Conference 2018","volume":"272S","author":"Hoeper","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40801-025-00488-9","article-title":"Comparative analysis of survival in pulmonary arterial hypertension for patients treated with selexipag in clinical practice (EXPOSURE Study)","volume":"12","author":"Soderberg","year":"2025","journal-title":"Drugs Real World Outcomes"},{"key":"10.1016\/j.jjcc.2025.12.022_bb0155","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jjcc.2023.08.004","article-title":"Association of delayed diagnosis of pulmonary arterial hypertension with its prognosis","volume":"83","author":"Kubota","year":"2024","journal-title":"J Cardiol"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725003272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725003272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T03:36:41Z","timestamp":1783222601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508725003272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0914508725003272"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.12.022","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world treatment practices of selexipag and parenteral prostacyclin (PGI2) analogs for pulmonary arterial hypertension in Japan: Retrospective study of the Japan PH Registry","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of Japanese College of Cardiology.","name":"copyright","label":"Copyright"}]}}